Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Yi Wang
Weill Medical Coll of Cornell Univ, Department: Radiation Diagnostic/oncology
Should you be removed from our database? Contact us at [email protected]. Read more below.
MedImageMetric, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The propose of this study is to deliver first-line of chemotherapy (PTX) by novel carriers specific to ICAM-1. To investigate the efficacy of combination therapy, we will also use a multi-tyrosine kinase inhibitor, Sorafenib, which is currently undergoing clinical studies for the treatment of advanced thyroid cancers. The second aim of the study includes validating the accuracy of the QSM technique by comparison of QSM measurement of CAPS distribution with post-mortem mapping of radiolabeled CAPS. Dr. Wang is the co-inventor of the QSM technique used in the study. Cornell recently licensed the QSM technology to MedImageMetric, a company that Dr. Wang has equity interests in.
Theranostic nanoparticles for the treatment of RAI refractory thyroid cancer
The treatment of most cancers is directed towards surgical resection, radiation, chemotherapy, or a multimodal therapy approach. Therapeutic techniques continue to lack selective delivery of targeted therapeutic agents, and are inadequate in mapping drug distribution in the body. We propose targeted therapy and quantitative imaging of drug distribution for novel treatment of aggressive thyroid cancers.
Filed on December 19, 2017.
Tell us what you know about Yi Wang's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Yi Wang filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Yi Wang | Weill Medical Coll of Cornell Univ | Conflict of Interest | MedImageMetric | $10,000 - $19,999 |
| Yi Wang | Weill Medical Coll of Cornell Univ | Conflict of Interest | MedImageMetric | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.